- ALINA: Efficacy and safety of adjuvant alectinib versus chemotherapy in patients with early-stage ALK plus non-small cell lung cancer (NSCLC)Solomon, B. J.; Ahn, J. S.; Dziadziuszko, R.; Barlesi, F.; Nishio, M.; Lee, D. H.; Lee, J. S.; Zhong, W. Z.; Horinouchi, H.; Mao, W.; Hochmair, M. J.; De Marinis, F.; Migliorino, M. R.; Bondarenko, I.; Lohmann, T. O.; Xu, T.; Gavaldon, A. Cardona; Bordogna, W.; Ruf, T.; Wu, Y. L.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), Barcelona, SPAIN, 2023-10-20 To 2023-10-24.被引 3
- ctDNA analysis of SAF-189s efficacy in ALK plus advanced nonsmall cell lung cancer (NSCLC)Yang, J-J.; Zhou, J.; Cheng, Y.; Li, M.; Zhao, Q.; Zhang, Z-Y.; Zang, A.; Fan, Y.; Zhou, Y.; Guo, J.; Zheng, Y.; Wu, Z.; Sun, J.; Xiang, X.; Wang, X.; Wu, Y-L.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), Barcelona, SPAIN, 2023-10-20 To 2023-10-24.
- Osimertinib as adjuvant therapy in patients (pts) with stage IB-IIIA EGFR mutation positive (EGFRm) NSCLC after complete tumor resection: ADAURAGrohe, C.; Herbst, R. S.; Tsuboi, M.; John, T.; Majem, M.; Goldman, J. W.; Kim, S. -W.; Marmol, D.; Rukazenkov, Y.; Wu, Y. -L.; Engel-Riedel, W.
会议论文
Efficacy and safety of adjuvant alectinib vs platinum-based chemotherapy (CT) in patients (pts) from Asia with resected, early-stage ALK plus non-small cell lung cancer (NSCLC): A sub analysis of ALINA
14阅读
